6:54 PM
 | 
May 09, 2014
 |  BC Extra  |  Clinical News

Pfizer reports Phase II data for meningitis B vax

Pfizer Inc. (NYSE:PFE) reported data from a pair of Phase II trials evaluating rLP2086 to vaccinate adolescents against meningococcal disease caused by Neisseria meningitidis serogroup B. One month after the last dose...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >